Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria AJ Thompson, BL Banwell, F Barkhof, WM Carroll, T Coetzee, G Comi, ... The Lancet Neurology 17 (2), 162-173, 2018 | 6760 | 2018 |
Defining the clinical course of multiple sclerosis: the 2013 revisions FD Lublin, SC Reingold, JA Cohen, GR Cutter, PS Sørensen, ... Neurology 83 (3), 278-286, 2014 | 3758 | 2014 |
Randomized trial of oral teriflunomide for relapsing multiple sclerosis P O'Connor, JS Wolinsky, C Confavreux, G Comi, L Kappos, TP Olsson, ... New England Journal of Medicine 365 (14), 1293-1303, 2011 | 1270 | 2011 |
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double‐blind placebo‐controlled multicenter trial K Hawker, P O'Connor, MS Freedman, PA Calabresi, J Antel, J Simon, ... Annals of neurology 66 (4), 460-471, 2009 | 1036 | 2009 |
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes L Kappos, CH Polman, MS Freedman, G Edan, HP Hartung, DH Miller, ... Neurology 67 (7), 1242-1249, 2006 | 1022 | 2006 |
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ... The Lancet 391 (10127), 1263-1273, 2018 | 966 | 2018 |
Differential diagnosis of suspected multiple sclerosis: a consensus approach DH Miller, BG Weinshenker, M Filippi, BL Banwell, JA Cohen, ... Multiple Sclerosis Journal 14 (9), 1157-1174, 2008 | 931 | 2008 |
A full genome search in multiple sclerosis GC Ebers, K Kukay, DE Bulman, AD Sadovnick, G Rice, C Anderson, ... Nature genetics 13 (4), 472-476, 1996 | 852 | 1996 |
Quantifying axonal loss after optic neuritis with optical coherence tomography F Costello, S Coupland, W Hodge, GR Lorello, J Koroluk, YI Pan, ... Annals of Neurology: Official Journal of the American Neurological …, 2006 | 773 | 2006 |
Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis M Duddy, M Niino, F Adatia, S Hebert, M Freedman, H Atkins, HJ Kim, ... The Journal of Immunology 178 (10), 6092-6099, 2007 | 767 | 2007 |
Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement MS Freedman, EJ Thompson, F Deisenhammer, G Giovannoni, ... Archives of neurology 62 (6), 865-870, 2005 | 754 | 2005 |
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the … L Kappos, MS Freedman, CH Polman, G Edan, HP Hartung, DH Miller, ... The Lancet 370 (9585), 389-397, 2007 | 734 | 2007 |
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial C Confavreux, P O'Connor, G Comi, MS Freedman, AE Miller, TP Olsson, ... The Lancet Neurology 13 (3), 247-256, 2014 | 683 | 2014 |
Vitamin D as an early predictor of multiple sclerosis activity and progression A Ascherio, KL Munger, R White, K Köchert, KC Simon, CH Polman, ... JAMA neurology 71 (3), 306-314, 2014 | 681 | 2014 |
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial F Lublin, DH Miller, MS Freedman, BAC Cree, JS Wolinsky, H Weiner, ... The Lancet 387 (10023), 1075-1084, 2016 | 490 | 2016 |
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 … L Kappos, MS Freedman, CH Polman, G Edan, HP Hartung, DH Miller, ... The Lancet Neurology 8 (11), 987-997, 2009 | 460 | 2009 |
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses PW O’connor, D Li, MS Freedman, A Bar-Or, GPA Rice, C Confavreux, ... Neurology 66 (6), 894-900, 2006 | 459 | 2006 |
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein KC O'Connor, KA McLaughlin, PL De Jager, T Chitnis, E Bettelli, C Xu, ... Nature medicine 13 (2), 211-217, 2007 | 423 | 2007 |
Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study B Banwell, L Krupp, J Kennedy, R Tellier, S Tenembaum, J Ness, ... The Lancet Neurology 6 (9), 773-781, 2007 | 421 | 2007 |
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial P Vermersch, A Czlonkowska, LME Grimaldi, C Confavreux, G Comi, ... Multiple Sclerosis Journal 20 (6), 705-716, 2014 | 393 | 2014 |